REFERENCES
- Schmidt MI, Hadji-Georgopoulos A, Rendell M, Margolis S, Kowarski A. The dawn phenomenon, an early morning glucose rise: implications for diabetic intraday blood glucose variation. Diabetes Care 1981; 4: 579–85.
- Olsson PO, Arnqvist H, von Schenck H, Ottosson AM. Overnight metabolic control with bedtime injection of intermediate-acting insulin or contin-uous subcutaneous insulin infusion. Diabetes Care 1987; 10: 702–6.
- Haakens K, Hanssen KF, Dahl-Jorgensen K, Vaaler S, Torjesen P, Try K. Early morning glycaemia and the metabolic consequences of delaying breakfast/morning insulin. A comparison of continuous subcutaneous insulin infusion and multiple injection therapy with human isophane or human ultralente insulin at bedtime in insulin-dependent diabetics. Scand J Clin Lab Invest 1989; 49: 653–9.
- Haakens K, Hanssen KF, Dahl-Jorgensen K, Vaaler S, Aagenaes 0, Mosand R. Continuous subcutaneous insulin infusion (CSII), multiple injections (MI) and conventional insulin therapy (CT) in self-selecting insulin-dependent diabetic patients. A comparison of metabolic control, acute complications and patient preferences. J Intern Med 1990; 228: 457–64.
- Zinman B, Ross S, Campos RV, Strack T. Effectiveness of human ultralente versus NPH insulin in providing basal insulin replacement for an insulin lispro multiple daily injection regimen. A double-blind randomized prospective trial. The Canadian Lispro Study Group. Diabetes Care 1999; 22: 603–8.
- Binder C. Absorption of injected insulin: a clinical-pharmacological study. Acta Pharmacol et Toxicol 1969; 27 Suppl 2: 1— 84.
- Hildebrandt P, Berger A, Volund AA, Kahl C. The subcutaneous absorption of human or bovine ultralente insulin formulations. Diabetic Med 1985; 2: 355–9.
- Owens DR, Vora JP, Heding LG, Luzio S, Ryder REJ, Atiea J, Hayes TM. Human, porcine and bovine ultralente insulin: Subcutaneous adminis-tration in normal man. Diabetic Med 1986; 3: 316 — 9.
- Seigler DE, Olsson GM, Agramonte RF, Lohman VL, Ashby MH, Reeves ML, Skyler JS. Pharma-cokinetics of long-acting (ultralente) insulin pre-parations. Diab Nutr Metab 1991; 4: 267–73.
- Holman RR, Steemson J, Darling P, Reeves WG, Turner RC. Human ultralente insulin. Br Med J 1984; 288: 665–8.
- Arnqvist H, Olsson PO, von Schenck H. Free and total insulin as determined after precipitation with polyethlene glycol: analytical characteristics and effects of sample handling and storage. Clin Chem 1987; 33: 93–6.
- Arnqvist HJ, Halban PA, Mathiesen UL, Zahnd G, von Schenck H. Hypoglycaemia caused by atypical insulin antibodies in a patient with benign monoclonal gammopathy. J Intern Med 1993; 234: 421–7.
- Smith CP, Dunger DB, Mitten S, Hewitt J, Spowart K, Grant DB, Savage MO. A comparison of morning and bed-time ultralente administration when using multiple injections in adolescence. Diabetic Med 1988; 5: 352–5.
- Freeman SL, O'Brien PC, Rizza RA. Use of human ultralente as the basal insulin component in treatment of patients with IDDM. Diabetes Res Clin Pract 1991; 12: 187–92.
- Tunbridge FKE, Newens A, Home PD, Davis SN, Murphy M, Burrin JM, Alberti KGMM, Jensen I. A comparison of human ultralente- and lente-based twice-daily injection regimens. Diabetic Med 1989; 6: 496–501.
- Parillo M, Mura A, Iovine C, Rivellese AA, Iavicoli M, Riccardi G. Prevention of early-morning hyperglycemia in IDDM patients with long-acting zinc insulin. Diabetes Care 1992; 15: 173–7.
- Binder C, Lauritzen T, Faber 0, Pramming S. Insulin pharmacokinetics. Diabetes Care 1984; 7: 188— 99.
- Markussen J, Havelund S, Kurtzhals P, Andersen AS, Halstrom J, Hasselager E, Larsen UD, Ribel U, Schaffer L, Vad K, Jonassen I. Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs. Diabetologia 1996; 39: 281 — 8.
- Hamilton-Wessler M, Ader M, Dea M, Moore D, Jorgensen PN, Markussen J, Bergman RN Diabetologia 1999; 42: 1254–63
- Rosskamp RH, Park G. Long-acting insulin analogs. Diabetes Care 1999; 22 Suppl 2: 109— 13.